The chemical class of LLGL4 inhibitors comprises a specialized group of compounds designed to interact with and inhibit the function of the LLGL4 protein, a member of the Lethal giant larvae (Lgl) family, which plays a critical role in maintaining cell polarity and has been implicated in various cellular processes including cell proliferation and differentiation. These inhibitors are characterized by their ability to specifically bind to the LLGL4 protein, thereby blocking its interaction with other cellular components necessary for its normal function. The design and development of these inhibitors utilize cutting-edge chemical synthesis, molecular biology, and computational modeling techniques to ensure high specificity and efficacy against the LLGL4 protein. Through targeted inhibition, these compounds can modulate cellular pathways in which LLGL4 is involved, providing valuable insights into the protein's role in cellular processes and offering potential avenues for the study of diseases associated with LLGL4 dysregulation.
The identification and optimization of LLGL4 inhibitors involve an array of sophisticated research methodologies, including high-throughput screening for initial compound discovery, structure-based compound design to improve specificity and reduce off-target effects, and various in vitro assays to evaluate biological activity and toxicity. Advanced techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy are employed to elucidate the molecular interactions between the inhibitors and the LLGL4 protein, facilitating the refinement of inhibitor design. Furthermore, cellular assays are used to assess the impact of these inhibitors on LLGL4-mediated processes, providing insights into the potential consequences of LLGL4 inhibition in physiological and pathological contexts. This rigorous scientific approach ensures a deep understanding of the mechanism of action of these inhibitors, laying the groundwork for future research into their potential as tools for elucidating the biological functions of LLGL4.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Inhibits protein transport from the endoplasmic reticulum to the Golgi apparatus, indirectly affecting vesicle trafficking. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $65.00 $162.00 $650.00 $2550.00 | 109 | |
Inhibits the V-ATPase, affecting acidification of organelles and indirectly impacting vesicle trafficking. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Inhibits dynamin, a GTPase involved in vesicle scission, indirectly impacting vesicle trafficking and exocytosis. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $82.00 $291.00 | 4 | |
Inhibitor of the exocyst complex, indirectly affecting vesicle docking and fusion processes. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $260.00 $799.00 | 36 | |
Disrupts actin polymerization, indirectly affecting vesicle movement and exocytosis. | ||||||
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $68.00 $210.00 $780.00 $1880.00 | 19 | |
Alkylates free sulfhydryl groups of cysteine residues, affecting SNARE complex formation and vesicle fusion. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $273.00 | 6 | |
Inhibits cytohesins, impacting ARF-GTPase signaling and indirectly affecting vesicle trafficking. | ||||||